马来酸氟伏沙明联合MECT及阿立哌唑治疗强迫症临床疗效分析

Clinical efficacy of fluvoxamine maleate and MECT combined with aripiprazole in the treatment of obsessive-compulsive disorder

目的探讨马来酸氟伏沙明联合无抽搐电休克及阿立哌唑治疗强迫症患者的临床疗效.方法将94例强迫症患者按照随机数字表法分为观察组与对照组,各47例.两组均给予马来酸氟伏沙明联合无抽搐电休克治疗,观察组在此基础上联合阿立哌唑治疗.比较治疗前后两组Yale-Browm强迫症状量表及汉密顿抑郁量表评分,统计两组患者治疗总有效率和不良反应发生率.结果治疗后两组Yale-Browm强迫症状量表及汉密顿抑郁量表评分均显著低于治疗前(P<0.01),观察组较对照组下降更显著(P<0.01).观察组总有效率显著高于对照组(P<0.05),两组患者不良反应发生率比较差异无统计学意义(P>0.05).结论马来酸氟伏沙明联合无抽搐电休克及阿立哌唑治疗强迫症临床疗效显著,且不会增加不良反应,具有临床推广价值.

Objective To observe the clinical efficacy of fluvoxamine maleate and MECT combined with aripiprazole in the treatment of obsessive-compulsive disorder.Methods 94 OCD patients were randomly divided into the observation group and the control group,47 cases each.Both groups were given fluvoxamine maleate in combination with MECT.The observation group was treated with aripiprazole on this basis.Yale-Browm OCD symptom scale and HAMD score before and after treatment of the two groups were compared.The total effective rate of treatment and the incidence of adverse reactions were compared between the two groups.Results After treatment,the Yale-Browm OCD symptom scale and HAMD scores were significantly,lower than those before treatment(P<0.01).The observation group decreased more sign Cicandy than the control group(P<0.01).The total effective rate of the observation group was significantly higher than that of the control group(PV0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Fluvoxamine maleate and MECT combined with aripiprazole have significant clinical efficacy in the treatment of obsessive-compulsive disorder,and do not increase adverse reactions,and have clinical value.